Read the latest positive news, breakthroughs, and inspiring stories about hepatitis b, curated daily by BrightWire.
Scientists developed a treatment that switches off hepatitis B virus genes without cutting DNA, keeping 90% of treated mice virus-free for at least six months. The first human patient received the experimental therapy this year in an ongoing clinical trial.
New research reveals that infections cause 12% of all cancer cases worldwide, and many could be prevented with vaccines we already have. Countries with high HPV vaccination rates are seeing cancer cases disappear entirely in young adults.
After 40 years of prevention-only treatments, European researchers are developing the first therapies that could free 254 million people from lifelong hepatitis B. Two major clinical trials show new immune-based approaches may finally achieve what vaccines alone couldn't: a functional cure.
Nigeria's Kano State is pioneering a bold campaign to stop babies from catching HIV, Hepatitis B, and syphilis from their mothers during pregnancy and birth. The breakthrough strategy combines early testing, free treatment, and vaccines that health officials say could eliminate these preventable infections entirely.
For the first time, a new treatment called bepirovirsen has achieved functional cure in 1 in 5 hepatitis B patients, compared to nearly zero with current therapies. This breakthrough could free millions from lifelong daily medication.
A groundbreaking hepatitis B treatment has achieved what was once thought impossible: completely clearing the virus from patients' bodies. One in five participants in recent trials are now virus-free, offering hope to 296 million people worldwide living with chronic hepatitis B.
A new drug has functionally cured chronic hepatitis B in one in five patients, offering hope for the 254 million people living with the world's most common liver infection. The FDA is expected to decide on approval by October 2026.
An experimental medicine called bepirovirsen achieved functional cures in nearly 20% of chronic hepatitis B patients during clinical trials, a massive leap from current treatments that cure only 1% to 3%. For a disease killing 1 million people annually, this breakthrough could transform millions of lives.
A breakthrough medication called bepirovirsen has functionally cured 20% of chronic hepatitis B patients within one year, marking the first major treatment advance in decades. The FDA is expected to decide on approval this October.
A groundbreaking hepatitis B treatment is letting patients stop therapy while keeping the deadly liver virus undetectable. The experimental drug achieved a "functional cure" in 20% of trial participants, a breakthrough decades in the making.
A groundbreaking treatment has achieved functional cures in one-fifth of chronic hepatitis B patients, offering hope for a disease that affects 296 million people worldwide. The weekly injection made the virus undetectable even after treatment stopped.
A groundbreaking hepatitis B treatment is helping one in five patients stop therapy entirely while keeping the deadly liver virus undetectable. After decades of searching, researchers may have found the path to a functional cure for a disease that kills 1.1 million people yearly.